Antibodies have long represented the ‘gold standard’ for regulatory bioanalysis of therapeutic proteins. Yet, they are associated with a number of limitations, including development time, manufacturing complexity and lack of batch reproducibility.
Our new application note details Covance’s validation to regulatory standards of an anti-idiotypic Affimer binder to Trastuzumab as part of a bioanalytical assay. Here Covance demonstrated the validity of Affimer binders as alternative or complimentary reagents to traditional antibodies within regulated PK assays, showing:
Download the application note by completing the form.
*By registering your email you agree to receive further updates from Avacta Life Sciences about our products and services which are specific to your areas of interest.